Dermatology
Arctic Therapeutics hf. supports clinical research in acne vulgaris, with interest in topical treatment approaches that address inflammatory and non-inflammatory skin lesions, as well as clinical assessment of visible disease improvement.
- Acne vulgaris
- Topical therapy
- Inflammatory lesions
- Non-inflammatory lesions
Its dermatology portfolio centers on treatment evaluation in adult patients with active facial and truncal skin disease.
Neurodegenerative disease
The sponsor is involved in research for Alzheimer’s disease, with a focus on neurological safety, brain imaging findings, and biomarkers linked to disease-related changes in the central nervous system.
- Alzheimer’s disease
- MRI imaging
- ARIA H
- ARIA E
This area reflects interest in clinical monitoring of neurodegenerative pathology and treatment-related brain effects.
Rare amyloid disorders
Arctic Therapeutics hf. also funds studies in hereditary cystatin C amyloid angiopathy (HCCAA), a rare condition associated with cerebral bleeding risk and systemic amyloid-related pathology.
- Hereditary cystatin C amyloid angiopathy (HCCAA)
- Cerebral bleeding events
- Amyloid-cystatin C complexes
- Biomarker analysis
Research in this field includes clinical and tissue-based evaluation of amyloid burden and vascular complications.
Biomarker and translational research
Across its active studies, the company places emphasis on biomarker-based assessment, including skin-derived markers, protein aggregation measures, and laboratory methods used to track biological response.
- Skin biopsy biomarkers
- Collagen-related markers
- Cell surface activation markers
- Protein aggregation
This research area links clinical outcomes with measurable molecular changes in both skin and neurological disease settings.
